What does this research mean for the field?

Proteogenomic profiling of treatment-naïve breast cancer biopsies can identify predictive biomarkers and therapeutic targets for precision oncology, particularly in HER2+ and TNBC cases. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The study aims to utilize proteogenomic profiling of treatment-naïve breast cancer biopsies to identify biomarkers predictive of pathological complete response (pCR) following neoadjuvant chemotherapy.

February 22, 2026Clinical Cancer Research

Abstract PS2-10-06: Proteogenomic profiling of treatment-naïve breast cancer biopsies from patients receiving neoadjuvant chemotherapy

View Full Paper

Ask AI

Bookmark

The study aims to utilize proteogenomic profiling of treatment-naïve breast cancer biopsies to identify biomarkers predictive of pathological complete response (pCR) following neoadjuvant chemotherapy.
Conducted microscaled proteogenomic profiling on 51 treatment-naive primary breast tumor biopsies.
Subtyped tumors via immunohistochemistry into HER2+, HR+, or TNBC categories.
Employed multi-omics analysis, including whole-exome sequencing, RNA sequencing, and mass spectrometry-based proteomics.
Utilized both data-dependent acquisition and data-independent acquisition techniques for proteomics.
Achieved the highest pCR rate of 69% in HER2+ tumors treated with dual antibody therapy.
Identified that non-pCR tumors exhibited significantly different protein levels, including higher levels of epithelial-mesenchymal transition proteins.
Noted that TNBC tumors had an overall pCR rate of 35%, significantly improving to 56% with pembrolizumab treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Explores proteogenomic profiling to identify predictive biomarkers for treatment response in breast cancer patients receiving neoadjuvant chemotherapy, implying potential for tailored...

Cite This Study

Jaehnig et al. (2026) studied this question.

synapsesocial.com/papers/699a9e20482488d673cd48a9 https://doi.org/10.1158/1557-3265.sabcs25-ps2-10-06

View Full Paper

Ask AI

Bookmark

Implication

Explores proteogenomic profiling to identify predictive biomarkers for treatment response in breast cancer patients receiving neoadjuvant chemotherapy, implying potential for tailored...

Abstract PS2-10-06: Proteogenomic profiling of treatment-naïve breast cancer biopsies from patients receiving neoadjuvant chemotherapy

Key Points

Discussion

Implication

Cite This Study

Abstract PS2-10-06: Proteogenomic profiling of treatment-naïve breast cancer biopsies from patients receiving neoadjuvant chemotherapy

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider